Aim. To develop a Russian version of MPN10 form for patients with myeloproliferative neoplasms (MPN) compliant with international recommendations. Materials & Methods. The study included 57 patients treated in 2019 at the Hematology Center of Botkin Hospital (n = 30) and the Russian Research Institute of Hematology and Transfusiology (n = 27). Among them there were 36 myelofibrosis, 9 polycythemia vera, and 12 essential thrombocythemia patients. Mean age of the patients was 54.6 years (standard deviation 15.9 years; age range 20-79 years). The male/female ratio was 23/34 (40.4 %/59.6 %). Underlying disease duration was from 1 month to 33 years (mean duration 7 years; standard deviation 8.6 years). Results. A stable structure and a high internal consistency of the form as well as its reproducibility as a tool were demonstrated. The study also confirmed its convergent and discriminant validity and satisfactory sensitivity to changes in a patient's status. Conclusion. The Russian MPN10 version can be used for symptom assessment in MPN patients in clinical practice and scientific research.